European Association for Cancer Research (EACR) 2025 | Booth 23
Connect with us at EACR 2025 to see how our solutions are transforming the understanding of cancer
Spatial Predictors of Immunotherapy Response in Triple-Negative Breast Cancer
Monday, June 16 | 1:15–2:00 pm
Auditorium VIII
Unraveling the TNBC puzzle: Can we better predict patient response to ICB therapy? Join Giampaolo Bianchini, MD, from San Raffaele Hospital, as he explores how Imaging Mass Cytometry™ (IMC™) technology is unlocking deep insights into the tumor microenvironment – advancing precision immuno-oncology where traditional methods fall short.
Key highlights:
- Hear about groundbreaking findings from a recent study that used IMC technology to identify key predictors of ICB response in TNBC patients
- Discover how IMC goes beyond traditional techniques to reveal the intricate interplay between cancer cells and immune cells within the tumor
- Learn about the critical role of cell phenotype, activation state and spatial organization in determining ICB effectiveness
- Explore how IMC platforms can pave the way for personalized treatment strategies in TNBC and other cancers
GUEST SPEAKER
Giampaolo Bianchini, MD
Associate Professor, Vita-Salute San Raffaele University
Head of Breast Oncology, Department of Clinical Oncology, IRCCS San Raffaele Hospital
Dr. Giampaolo Bianchini is a medical oncologist with 15 years of clinical experience in breast cancer treatment. He has been a co-investigator in over 100 clinical trials and is the head of the breast cancer group and the clinical translational and immunotherapy research group at San Raffaele Hospital in Milan. He has a degree in general medicine and surgery and a specialization in medical oncology and has published over 45 papers on breast cancer.
See our technology in action
Poster No. |
Title |
Date |
Session |
|---|---|---|---|
|
P-483 |
Accelerating Immuno-Oncology Research with Flexible Workflows Using Modular Flex-Fit™ CyTOF Panels | June 17 | IMMUNOTHERAPY |
|
P-585 |
A Deep-Learning Approach for Tissue Mapping and Cell Phenotyping in Imaging Mass Cytometry Data Analysis | June 17 | TRANSLATIONAL RESEARCH |
|
P-530 |
Advancing CAR T Clinical Development with High-Parameter CyTOF™ Technology | June 18 | IMMUNOTHERAPY |
|
P-620 |
Imaging Mass Cytometry Detects the True Dynamic Range of Low-Abundance Biomarker Expression in Human Tumors | June 18 | TRANSLATIONAL RESEARCH |
|
P-739 |
Spatial Profiling of Exhausted T Cells Using High-Plex Imaging Mass Cytometry | June 18 | TUMOUR BIOLOGY |
Connect with us at EACR 2025
Come visit us at Booth 23 to chat about how our technologies are translating scientific discoveries from bench to bedside to drive progress in cancer research.
Our high-content solutions in serum, spatial and single-cell proteomics and multi-omics offer the highest levels of content, precision and unique scalability in the life science industry.
Defining standards
Our industry-leading proteomic and multi-omic solutions that scale
Every marker, all at once
Our industry-leading proteomic and multi-omic solutions
that scale
High-resolution spatial proteomics
Highest dynamic range and throughput
Ultrahigh-plex precision proteomics
Enable 11,000 protein measurements with unparalleled reproducibility
High-throughput genomic profiling
The only hands-free, walk-away qPCR system
Interested in talking with an expert?
Unless explicitly and expressly stated otherwise, all products are provided for Research Use Only, not for use in diagnostic procedures. Find more information here.
Not affiliated with or endorsed by European Association for Cancer Research® (EACR) Annual Meeting 2025.